Detalles de la búsqueda
1.
Long-read sequencing for non-small-cell lung cancer genomes.
Genome Res
; 30(9): 1243-1257, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32887687
2.
Impacts of the STING-IFNAR1-STAT1-IRF1 pathway on the cellular immune reaction induced by fractionated irradiation.
Cancer Sci
; 113(4): 1352-1361, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35133062
3.
Report of the use of patient-derived xenograft models in the development of anticancer drugs in Japan.
Cancer Sci
; 111(9): 3386-3394, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639672
4.
Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint.
Mol Cell
; 45(5): 680-95, 2012 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-22405274
5.
2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
Bioorg Med Chem
; 25(14): 3658-3670, 2017 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28533114
6.
Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones.
Bioorg Med Chem
; 25(7): 2133-2147, 2017 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28284870
7.
Design and synthesis of fused bicyclic inhibitors targeting the L5 loop site of centromere-associated protein E.
Bioorg Med Chem Lett
; 26(17): 4296-300, 2016 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27476141
8.
Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map.
Bioorg Med Chem
; 21(17): 5488-502, 2013 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23816042
9.
Wnt activation disturbs cell competition and causes diffuse invasion of transformed cells through NF-κB-MMP21 pathway.
Nat Commun
; 14(1): 7048, 2023 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37923722
10.
CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade.
Nat Commun
; 14(1): 7490, 2023 11 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37980406
11.
Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.
Gastroenterology
; 140(4): 1303-1313.e1-3, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21199651
12.
Single-Cell Analyses Reveal Diverse Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer.
Cancer Res
; 81(18): 4835-4848, 2021 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34247147
13.
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery.
Sci Adv
; 7(21)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34020950
14.
Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens.
Sci Rep
; 11(1): 341, 2021 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33431933
15.
Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
Sci Rep
; 10(1): 21762, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33303839
16.
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent.
J Med Chem
; 63(3): 1084-1104, 2020 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31895562
17.
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Mol Cancer Res
; 17(11): 2233-2243, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31467113
18.
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor.
Sci Adv
; 5(5): eaav3660, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31131319
19.
TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma.
Oncotarget
; 9(26): 18480-18493, 2018 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29719619
20.
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
Cancer Res
; 65(2): 417-26, 2005 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15695382